
Gameto, founded in 2020 by Dr. Dina Radenkovic Turner and Martin Varsavsky, uses cell engineering to develop treatments for women’s reproductive health, starting with infertility and expanding into ovarian disease and menopause. Gameto has raised $127 million to date, including a $44 million Series C in August 2025 to complete the U.S. Phase 3 trial of its lead program.
The lead program is Fertilo, which uses stem cell–derived ovarian support cells to mature eggs outside the body. Instead of roughly two weeks of daily hormone injections, patients need just two to three days, making IVF faster and less demanding. Fertilo is already cleared in markets including Australia, Japan, Mexico and Peru, and is in a U.S. Phase 3 trial, with early results expected by the end of 2026. Gameto is also developing therapies for menopause.
For Ferring, the acquisition builds on decades of work in fertility care. Ferring is a leader in reproductive medicine and maternal health, with fertility treatments such as Menopur and Endometrin, as well as Cervidil, which is used to prepare the cervix for labor induction. Menopur, the company’s flagship product, drove much of Ferring’s growth in 2025, and Ferring's reproductive medicine business surpassed €1 billion in annual sales in 2024. Chairman and CEO Jean-Frédéric Paulsen describes the acquisition as a way to advance new approaches in fertility care and reach more patients worldwide.

By acquiring Gameto, Ferring is choosing to own the next generation of fertility care. That fits a long pattern of backing fertility startups and incubators. Ferring has invested in Robyn, a pre-seed startup supporting people through fertility and family-building, and partnered with HoMu Health Ventures to incubate startups focused on reproductive and maternal health. Fertility companies now have a credible strategic exit path, a huge win for Amboy’s fertility portfolio and early-stage fertility innovators.
For founders, the deal shows that incumbents in reproductive medicine will commit significant capital to platform science before U.S. commercialization, creating a credible strategic exit path for early-stage fertility companies.
Some early-stage players in fertility and reproductive health:
Granata Bio (Series B) — Fertility-focused biopharma building a pipeline of IVF medications to expand access and choice for fertility patients (Amboy Street Portfolio Company)
U-Ploid (Series A) — Oxford-based biotech developing Lyvanta, a first-in-class therapeutic designed to improve egg quality by reducing age-related chromosomal errors during IVF
Ovo Labs (Series A) — Advancing three egg rejuvenation therapeutics through preclinical development to improve the chance of IVF success in patients over 35.
We look forward to keeping you updated as we invest in the $1T women's health and sexual health space.


